Navigation Links
BioMarin Announces FDA Approval for Kuvan
Date:12/13/2007

ired for the metabolism of phenylalanine, an essential amino acid found in most protein-containing foods. If the active enzyme is not present in sufficient quantities, Phe accumulates to abnormally high levels in the blood and becomes toxic to the brain, resulting in a variety of complications including severe mental retardation and brain damage, mental illness, seizures, tremors, and limited cognitive ability. As a result of newborn screening efforts implemented in the 1960s and early 1970s, virtually all PKU patients under the age of 40 in developed countries have been diagnosed at birth. Currently, PKU can only be managed by a Phe-restricted diet, which is supplemented by nutritional replacement products, like formulas and specially-manufactured foods; however, the strict diet is difficult for most patients to adhere to the extent needed for achieving adequate control of blood Phe levels. To learn more about PKU, please visit http://www.PKU.com. Information on this website is not incorporated by reference into this press release.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(TM) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the trea
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... NEW YORK , July 25, 2014  Smile ... selected to showcase their Virtual Surgery Simulator among ... 2014, which will take place in Washington, ... for the Performing Arts. "Smile Train ... BioDigital alongside the talented community of innovators in health ...
(Date:7/25/2014)... GrowBLOX Sciences, Inc. (OTCQB: GBLX) is pleased to announce the ... LLC, an Illinois limited liability company ... medical marijuana licenses in the state of Illinois ... 20% equity interest in LaurelCo, LLC in exchange for licenses ... well as all technology related to the machines and to ...
(Date:7/25/2014)...  Solanbridge Group Inc (OTC: SLNX) is pleased to ... Buzznbrewz.com and the Letter of Intent issued on July ... Purchase Agreement. Charles R. Shirley , ... have Mr. David Pecoraro and Buzznbrewz.com join ... private sector and developed a tremendous network of contacts ...
Breaking Medicine Technology:Smile Train and BioDigital Selected to Showcase Virtual Surgery Simulator in The Hive at TEDMED 2014 2Smile Train and BioDigital Selected to Showcase Virtual Surgery Simulator in The Hive at TEDMED 2014 3GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 2GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 3Solanbridge Group Inc Announces Acquisition of Buzznbrewz.com 2
... Genoptix, Inc. (Nasdaq: GXDX ), a specialized ... for the third quarter of 2009, which includes a ... primarily from strong cash collections related to prior period ... of $32.1 million for the comparable period in 2008, ...
... (Nasdaq: ROCM ) today announced operating results for its ... Company reported sales of $9,009,000 for the current quarter compared ... The Company reported a quarterly net loss of $229,000 or ... or $.03 per diluted share for the fourth quarter of ...
Cached Medicine Technology:Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 2Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 3Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 4Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 5Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 6Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 7Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 8Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 9Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 10Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 11Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 2Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 3Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 4Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 5Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 6Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 7Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 8Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 9Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 10Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 11Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 12
(Date:7/26/2014)... According to the Tinnitus ... this is a comprehensive guide that consists ... all types of disorders related to ... due to Ménière's disease ,     Objective ... tinnitus ,     Inner, middle or external ...
(Date:7/26/2014)... The U.S. Food & Drug Administration (FDA) has ... medication guide for AndroGel to include blood clots in the ... topical low testosterone medication, notes Wright & Schulte LLC. ... the low testosterone theapy drug, has also updated the official ... as signs of a blood clot in the leg and ...
(Date:7/26/2014)... July 26, 2014 According to the ... Vkool.com, this is a comprehensive guide that provides readers ... tattoos . This book also teaches them how to ... medical procedures in their own home for drastic results. ... Rid Tattoo Naturally" book includes step-by-step tutorials and product ...
(Date:7/25/2014)... 26, 2014 2014 Deep ... Permeation Chromatography Industry” is a professional and ... China Gel Permeation Chromatography market. The report ... Gel Permeation Chromatography definition, classification, application, and ... overview. This research covers the international market ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 A federal ... judgment in two DePuy Pinnacle hip lawsuits ( http://www.depuypinnacle-lawsuit.com/ ... for the claims to go before a jury on ... opinion rendered on July 18th, U.S. District Judge Ed ... the two Plaintiffs’ claims may proceed to trial against ...
Breaking Medicine News(10 mins):Health News:Tinnitus Miracle Book Review Exposes Thomas Coleman's Guide for Treating Tinnitus – Vkool.com 2Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 2Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 3Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 4Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 5Health News:"Get Rid Tattoo Naturally" Book Review Exposes Jason Carter's Tattoo Removal Guide – Vkool.com 2Health News:"Get Rid Tattoo Naturally" Book Review Exposes Jason Carter's Tattoo Removal Guide – Vkool.com 3Health News:2014 China & Global GPC Industry - Gel Permeation Chromatography Development Trends Now at DeepResearchReports.com 2Health News:2014 China & Global GPC Industry - Gel Permeation Chromatography Development Trends Now at DeepResearchReports.com 3Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 2Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 3Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 4
... a male child on Wednesday at Holtz Children's Hospital. The ... cordis. Seven or eight babies in a million are born ... was born with his heart outside his chest. The breast ... called pericardium had not developed in him. ,The ...
... here that would thrill every gourmet. It is great reading//,that ... It is a full course meal, daubed in rich, saucy ... ,Brian Wansink is the brain behind this unique literary piece, ... and Brand Laboratory. Truly a gourmet, who enjoys every kind ...
... has concluded that monitoring fetal oxygen when a woman is ... be more healthier or decrease the chances of an avoidable ... during labor, it has been a routine practice in modern ... fetus .This is done in the current view held by ...
... found anti-clotting drug called bivalirudin (Angiomax) that beats the ... syndromes such as heart// attacks. This new blood thinner ... acute coronary syndromes. ,The Results of the ... were published in November issue of the New England ...
... concluded that there is a genetic link between SARS in ... human beings through// civet cats. The results were revealed in ... ,The research that was carried out in six civet cats, ... and Guangzhou, in cooperation with the university of Hong Kong, ...
... Nestlé has decided to pump in funds to the tune ... the Federal Institute of Technology in Lausanne to invest in ... power of the brain. ,The joint venture, envisaged ... children. Also research to lessen the impact of brain degenerative ...
Cached Medicine News:Health News:Naseem’s Heart Put In Its Plac 2Health News:Whet your appetite with “Mindless Eating”: A gourmet's deligh 2Health News:Whet your appetite with “Mindless Eating”: A gourmet's deligh 3Health News:Fetal Oxygen Monitors Not Helpful To Prevent Mishaps In Labor:Says Study 2Health News:New Anti-Clotting Drug Less Risky For Heart Attack Patients 2
The Model 305 is a hand-held, portable, lightweight oximeter designed for spot checking. It has a NiCad rechargeable battery....
... expanded memory capabilities for overnight sleep screening., ... saturation and pulse rate data, and can operate ... needs:, ,1. The Model 130 can retain ... single patient, making the device ideally suited for ...
... inserting a finger into comfortable holder, ... and continuous measurement is performed., ... height. In darker surroundings, back light ... ,Light weight, compact contour and ...
... or spot check pulse oximetry ... an internal rechargeable battery. ... modes make it ideal for ... clinical environment; during emergency air ...
Medicine Products: